Uncategorized

Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR-T therapy

Published

on

ElevateBio will be the primary source of Kyverna’s autologous CAR-T cell therapy for anticipated U.S. and global launches in autoimmune indications.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version